Please enable Javascript
Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Prostate Cancer
Localized
mCSPC
CRPC
RLT
Prostate Cancer Diagnostics
Prostate Cancer
Localized
mCSPC
CRPC
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Advertisement
Urothelial Carcinoma Knowledge Hubs
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Roundtable Discussions
Management Round-Up: Translocation, Chromophobe, RMC, and Other Subtypes
Laurence Albiges, MD, PhD
nccRCC
|
July 26, 2024
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Laurence Albiges, MD, PhD
nccRCC
|
July 26, 2024
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
Managing Metastatic nccRCC: Historical Approaches and Current Changes
Laurence Albiges, MD, PhD
nccRCC
|
July 23, 2024
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
Defining and Prognosticating nccRCC: Constant Molecular Evolution
Laurence Albiges, MD, PhD
nccRCC
|
July 23, 2024
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
Refractory RCC: Third-Line Treatment Considerations
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Improving Outcomes in Patients With Chromophobe, Papillary RCC
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
View Full Archive
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Editor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Editor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Editor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Editor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Editor | Fellow at the University of Southern California
David Ambinder, MD
Editor | Urology Resident at New York Medical College/Westchester Medical Center